EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicine

Livia Concetti, Manuel Scimeca iD, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello iD, Giuseppe S Sica iD

Molecular Oncology · 2025-12 · 19 (12) · 3486-3498

DOI: 10.1002/1878-0261.70023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Oncology, online erschienen am 11.07.2025. Verfasst von Livia Concetti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, TOR, University of Rome "Tor Vergata", Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunity, Precision Medicine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health & MAECI Italy-China Science and Technology Cooperation, Associazione Italiana per la Ricerca sul Cancro, Lazio Innova.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is a heterogenous disease with distinct biological and clinical subgroups, each with different prognoses and responses to therapy. In this case report, taking inspiration from a case of locally advanced CRC with serine/threonine‐protein kinase B‐raf (BRAF) V600E mutation, we highlight an atypical consensus molecular subtype 1 (CMS1). Deep multi‐omic analyses showed a limited expression of programmed cell death protein 1 (PD‐1) and reduced T‐cell infiltration, including CD8 + and natural killer (NK) cells, in the analyzed CMS1 tumor. In parallel, a reduced activation of the JAK/STAT pathway was detected, suggesting a lack of clinical response to immunotherapy with checkpoint inhibitors. Furthermore, the finding of up‐regulated expression of WEE1 G2 checkpoint kinase (WEE1), checkpoint kinase 1 (CHK1), and checkpoint kinase 2 (CHK2), poly(ADP‐ribose) polymerase ( PARP ), and heat shock protein 90 ( HSP90 ) suggests a potential alternative therapeutic approach using inhibitors of the cell cycle, HSP90, or PARP in combination with conventional chemotherapy, targeted agents, or immunotherapy. This paradigmatic case should stimulate a regular deep omics analysis to improve precision medicine. We therefore suggest that full mutational and expression profiling analyses of CRC subtypes should be undertaken to improve therapeutic strategies in CRC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmunityPrecision MedicineHumansMultiomicsMutation

Stichwörter der Autor:innen

CMS1, immune responseJAK/STATcolorectal cancerpersonalized medicine

Autor:innen und Institutionen

  • Department of Experimental Medicine, TOR, University of Rome "Tor Vergata", Italy.
  • Indivumed GmbH, Falkenried, Hamburg, Germany.
  • Department of Surgical Science, University of Rome "Tor Vergata", Italy.
  • The Fourth Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Suzhou Medical College, Soochow University, Suzhou, China.

ORCID-Profile: Manuel Scimeca, Alessandro Mauriello, Giuseppe S Sica

Förderung

  • Ministry of Health & MAECI Italy-China Science and Technology Cooperation
  • Associazione Italiana per la Ricerca sul Cancro
  • Lazio Innova
  • MUR-PNRR M4C2I1.3 PE6 project PE00000019 Heal Italia
  • Fondazione AIRC per la ricerca sul cancro ETS

Zitieren

APA

Concetti, L., Scimeca, M., Bischof, J., Woodsmith, J., Agostini, M., Fiorani, C., Shi, Y., Candi, E., Melino, G., Mauriello, A., & Sica, G. S. (2025). Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicine. Molecular Oncology, 19(12), 3486-3498. https://doi.org/10.1002/1878-0261.70023

Vancouver

Concetti L, Scimeca M, Bischof J, Woodsmith J, Agostini M, Fiorani C, et al. Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicine. Molecular Oncology. 2025;19(12):3486-3498. doi:10.1002/1878-0261.70023

BibTeX
@article{Concetti2025,
  author = {Concetti, Livia and Scimeca, Manuel and Bischof, Julia and Woodsmith, Jonathan and Agostini, Massimiliano and Fiorani, Cristina and Shi, Yufang and Candi, Eleonora and Melino, Gerry and Mauriello, Alessandro and Sica, Giuseppe S},
  title = {Multi‐omic characterization of consensus molecular subtype 1 ( CMS1 ) colorectal cancer with dampened immune response improves precision medicine},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {12},
  pages = {3486--3498},
  doi = {10.1002/1878-0261.70023}
}
Kostenlos starten →